U.S. markets closed
  • S&P Futures

    +5.50 (+0.12%)
  • Dow Futures

    +38.00 (+0.10%)
  • Nasdaq Futures

    +10.00 (+0.06%)
  • Russell 2000 Futures

    +6.20 (+0.33%)
  • Crude Oil

    -0.15 (-0.21%)
  • Gold

    +7.20 (+0.36%)
  • Silver

    +0.05 (+0.21%)

    -0.0031 (-0.29%)
  • 10-Yr Bond

    +0.1160 (+2.81%)
  • Vix

    -0.71 (-5.44%)

    -0.0044 (-0.35%)

    +0.8440 (+0.59%)
  • Bitcoin USD

    -88.97 (-0.20%)
  • CMC Crypto 200

    +18.10 (+2.02%)
  • FTSE 100

    +40.75 (+0.54%)
  • Nikkei 225

    -550.44 (-1.68%)

Prothrombin Complex Concentrate Market Worth USD 1,604.9 Million at 10.6% CAGR; Industry Giants Such as Grifols and CSL to Focus on Enhancing Manufacturing Capacity: Fortune Business Insights™

Key Companies Covered in the Prothrombin Complex Concentrate Market Research Report Are Takeda Pharmaceutical Company Limited, Kedrion S.p.A, Octopharma AG, Grifols, S.A., China Biologic Products, Holdings, Inc., Sanquin, CSL Behring and other key market players.

Pune, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Global Prothrombin Complex Concentrate Market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast period. Sudden spike in the uptake of plasma-based therapies as a result of the COVID-19 pandemic is expected to benefit the market, shares Fortune Business Insights™ in its report, titled “Prothrombin Complex Concentrate Market Size, Share & COVID-19 Impact Analysis, By Product (3-factor PCC and 4-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency), By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics and Others), and Regional Forecast, 2020-2027”.

The report states that the value of the market was at USD 695.3 million in 2019. It also provides the following information:

  • Intelligent insights into the factors driving and restraining the market;

  • Careful examination of the market segments;

  • Comprehensive analysis of the regional dynamics shaping the market; and

  • Exhaustive assessment of the key market players and their dominant strategies.

Request a Sample Copy of the Research Report:

Industry Developments:

  • February 2020: Japan-based Takeda Pharmaceutical reiterated its commitment towards developing therapies in rare hematology at the European Association for Hemophilia and Allied Disorders’ 13th Annual Congress. The company aims at meeting the needs of the rising number of patients with undiagnosed hemophilia A & B in the UK, Germany, France, Italy, and Spain.

  • August 2018: The Spanish pharmaceutical major, Grifols, S.A., fully acquired Germany-based Biotech AG’s subsidiary, Biotest US, for an estimated value of USD 286 million. The acquisition will allow Grifols access to Biotest’s 22 plasma collection centers and all corporate offices across the US.

Prothrombin complex concentrate is a form of plasma treatment that is used to prevent bleeding in patients unable to form clots. COVID-19 patients having severe pneumonia have been found to be suffering from internal bleeding, with an inhibited ability for blood coagulation. As a result, the demand for plasma-derived therapies such as PCC, which have proven efficacy in dealing with blood disorders, is rising at a rapid rate during the current crisis. Plasma therapies are already being administered to coronavirus patients around the world and are meeting with notable success. This has surged the uptake of plasma-derived medications, drugs, and therapies, which is expected to feed the growth of this market.

Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit:

Market Driver

Increasing Prevalence of Hemophilia to Augment Market Growth

Hemophilia is a rare bleeding disorder that is characterized by the deficiency of blood-clotting proteins in a person. A study conducted by a team of international researchers, spearheaded by the McMaster University in Canada, found that over 1,125,000 men suffer from inherited hemophilia, which is three times higher than previously believed. Of these, approximately 418,000 are afflicted with the more severe variant of the disease, with the highest incidence of the disorder being observed in middle- and low-income countries.

This bodes well for the PCC market growth as the demand for plasma-derived factor IX, a vital blood clotting factor in hemophilia B patients, is steadily rising. For example, the World Federation of Hemophilia reported that more than 68,703,141 I.U. of plasma-derived factor IX were used in Europe in 2018. These developments are expected to prove favorable for the prothrombin complex concentrate market growth in the coming years.

Regional Insights

Supportive Regulatory Policies for Specialized Therapies to Accelerate Market in North America

North America, with a market size of USD 305.9 million in 2019, is expected to lead the global PCC market on account of strong support from the US Food and Drug Administration (FDA) for novel plasma-derived therapies. This favorable environment is encouraging pharmaceuticals in the region to ramp up their R&D spending and bring out specialized treatments and drugs for patients with blood disorders.

Europe is also expected to strengthen its hold on the prothrombin complex concentrate market share during the forecast period owing to the surging number of COVID-19 cases in the region. Large pharmaceuticals in the region such as Grifols are optimizing their production capacity and distribution networks to meet the escalating demand for plasma-based medication.

Quick Buy - Prothrombin Complex Concentrate Market Research Report:

Competitive Landscape

Focus on Superior and Advanced Therapies by Players to Intensify Competition

The competition in the market for prothrombin complex concentrate is monopolistic, owing to the presence and activities of a very few number of pharmaceutical companies. These companies are presently focusing on delivering advanced and superior treatment options of patients with blood disorders to further entrench their market position.

List of Players Covered in the Prothrombin Complex Concentrate Market Report:

  • Takeda Pharmaceutical Company Limited

  • Kedrion S.p.A

  • Octopharma AG

  • Grifols, S.A.

  • China Biologic Products Holdings, Inc.

  • Sanquin

  • CSL Behring

Have Any Query? Ask Our Experts:

Prothrombin Complex Concentrate Market Segmentations:

By Product Type

• 3-factor

• 4-factor

By Application

• Acquired Coagulation Factor Deficiency

• Congenital Coagulation Factor Deficiency

By End User

• Hospital & Ambulatory Surgical Centers

• Specialty Clinics

• Others

By Geography

• North America (the U.S. and Canada)

• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

• Latin America (Brazil, Mexico, and Rest of Latin America)

• The Middle East& Africa (South Africa, GCC, and Rest of the Middle East & Africa)

Get your Customized Research Report:

Have a Look at Related Reports:

Plasma Fractionation Market Share & Industry Analysis, By Product Type (Albumin, Immunoglobulin (Intravenous Immunoglobulin and Subcutaneous Immunoglobulin), Coagulation Factors, Protease Inhibitors and Others), By Application (Immunology & Neurology, Hematology, Critical Care, Pulmonology and Others), By End User (Hospitals & Clinics,) and Geography Forecast, 2019-2026

Hemophilia Drugs Market Share and Global Trend By Disease Indication (Hemophilia A, B & C), Therapy Type (Recombinant Therapy, Plasma therapy & Others), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2025

Drug Delivery Market Share & Industry Analysis, By Route of Administration (Injectable, Nasal, Topical & Transdermal, Oral and Others), By Type (Conventional and Advanced), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Regional Forecast, 2019-2026

Continuous Renal Replacement Therapy (CRRT) Market Share & Industry Analysis, By Product (Systems, and Consumables), By Modality (Slow Continuous Ultra-Filtration {SCUF}, Continuous Venovenous Hemofiltration {CVVH}, Continuous Venovenous Hemodialysis {CVVHD}, and Continuous Venovenous Hemodiafiltration {CVVHDF}), and Regional Forecast, 2019-2026

Contraceptive Devices Market Share and Global Trend By Product Type (Male & Female Contraceptive Devices, Technology (Hormonal & Barrier Contraceptives), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channels, Public Channel & NGO & Others) and Geography Forecast till 2025

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: